CAPR - Capricor signs intellectual property license for COVID-19 serology test platform

Clinical-stage biotech Capricor Therapeutics ([[CAPR]] +5.6%) has received a non-exclusive license to intellectual property, know-how and data related to a new imaging-based serology test platform for COVID-19 from Johns Hopkins University.This platform has been applied to the analysis of patient antibodies to multiple SARS-CoV-2 proteins, including spike, nucleocapsid, and membrane.Capricor plans to meet with the FDA soon to discuss the next steps towards clinical development for the platform."we plan to convert the current version of the serology test to a multiplexed imaging test for clinical applications within and beyond the scope of SARS-CoV-2, and we intend to explore the potential for partnership opportunities for our COVID-19 technology,” CEO Linda Marbán said.

For further details see:

Capricor signs intellectual property license for COVID-19 serology test platform